Allergan Inc (AGN) 240.22 $AGN
Why Pfizer Inc. Isn't Built to Last
George Budwell, The Motley Fool - Motley Fool - Sat Mar 21, 7:11AM CDT
Source: Wikimedia. Nearly all big pharma these days have been undergoing wholesale changes due to the patent cliff, the emergence of game-changing new classes of drugs, and payers leveraging their formularies to induce pricing wars. A direct...
AGN: 240.22 (+2.88), MRK: 58.58 (+0.37), AZN: 72.70 (+1.80), PFE: 34.25 (+0.10), GSK: 48.81 (+0.60)
Douglas Ingram of Allergan, Inc. Elected to the Board of Pacific Mutual Holding Company
Business Wire - Thu Mar 19, 3:05PM CDT
Pacific Life announced today that Douglas Ingram, former president of Allergan, Inc., has been elected to the board of Pacific Mutual Holding Company, the ultimate parent company of Pacific Life Insurance Company. His election is effective May 1, 2015.
AGN: 240.22 (+2.88)
Shares of AGN Up 43.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 19, 11:20AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 6 months, Allergan has returned 43.75% as of today's recent price of $240.22.
AGN: 240.22 (+2.88)
2010-2015 Myocardial Infarction Partnering Deals and Agreements Deals Analysis for the World's Leading Healthcare Companies
M2 - Thu Mar 19, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4q8bs6/myocardial) has announced the addition of the "Myocardial Infarction Partnering 2010-2015" report to their offering. The Myocardial Infarction Partnering 2010-2015 provides understanding and access to the myocardial infarction partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of myocardial infarction partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors myocardial infarction technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. In Myocardial infarction Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in myocardial infarction partnering Chapter 3 - Average deal terms for myocardial infarction Chapter 4 - Active myocardial infarction dealmakers Chapter 5 - Myocardial infarction dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/4q8bs6/myocardial
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Prostate Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 10:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6kbqqw/prostate_cancer) has announced the addition of the "Prostate Cancer Partnering 2010-2015" report to their offering. The Prostate cancer Partnering 2010-2015 provides understanding and access to the prostate cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of prostate cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors prostate cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in prostate cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 100 prostate cancer deals and contract documents where available - The leading prostate cancer deals by value since 2010 In Prostate cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Prostate cancer partnering Chapter 3 - Average deal terms for Prostate cancer Chapter 4 - Active Prostate cancer dealmakers Chapter 5 - Prostate cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/6k...ate_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Solid Tumor Partnering Deals and Agreements Anaysis for the World's Leading Healthcare Companies 2010-2015
M2 - Thu Mar 19, 10:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmmk8v/solid_tumor) has announced the addition of the "Solid Tumor Partnering 2010-2015" report to their offering. The Solid Tumor Cancer Partnering 2010-2015 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of solid tumor cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors solid tumor cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 200 links to online copies of actual solid tumor cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In Solid Tumor Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Solid tumor cancer partnering Chapter 3 - Average deal terms for Solid tumor cancer Chapter 4 - Active Solid tumor cancer dealmakers Chapter 5 - Solid tumor cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/bm...olid_tumor
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Lung Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rq7vtm/lung_cancer) has announced the addition of the "Lung Cancer Partnering 2010-2015" report to their offering. The Lung Cancer Partnering 2010-2015 provides understanding and access to the lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of lung cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lung cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in lung cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 190 lung cancer deala and contract documents where available - The leading lung cancer deals by value since 2010 In Lung Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Lung cancer partnering Chapter 3 - Average deal terms for Lung cancer Chapter 4 - Active Lung cancer dealmakers Chapter 5 - Lung cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/rq...ung_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Lymphoma Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5hkfxz/lymphoma) has announced the addition of the "Lymphoma Partnering 2010-2015" report to their offering. The Lymphoma Partnering 2010-2015 provides understanding and access to the lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of lymphoma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lymphoma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 100 links to online copies of actual lymphoma deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in lymphoma dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 100 lymphoma deals and contract documents where available - The leading lymphoma deals by value since 2010 In Lymphoma Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Lymphoma partnering Chapter 3 - Average deal terms for Lymphoma Chapter 4 - Active Lymphoma dealmakers Chapter 5 - Lymphoma dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/5hkfxz/lymphoma
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Multiple Myeloma Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bttdtp/multiple_myeloma) has announced the addition of the "Multiple Myeloma Partnering 2010-2015" report to their offering. The Multiple myeloma Partnering 2010-2015 provides understanding and access to the multiple myeloma partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of multiple myeloma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors multiple myeloma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in multiple myeloma dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 100 multiple myeloma contract documents - The leading multiple myeloma deals by value since 2010 In Multiple myeloma Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in multiple myeloma partnering Chapter 3 - Leading multiple myeloma deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/bt...le_myeloma
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Liver Cancer Partnering Deals and Agreements 2010-2015 - Analysis from the World's Leading Healthcare Companies
M2 - Thu Mar 19, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8sxzpx/liver_cancer) has announced the addition of the "Liver Cancer Partnering 2010-2015" report to their offering. The Liver Cancer Partnering 2010-2015 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in Liver cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 livercancer deals and contract documents where available - The leading Liver cancer deals by value since 2010 In Liver Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Liver cancer partnering Chapter 3 - Average deal terms for Liver cancer Chapter 4 - Active Liver cancer dealmakers Chapter 5 - Liver cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/8s...ver_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
This Exciting Biotech Isn't Built to Last
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Mar 19, 7:04AM CDT
Source: Flickr, Courtesy of Creative Commons The performance of an exciting biotech can really pack some punch in your portfolio, but some of them simply aren't built to last. One candidate for that category is San Diego-based Acadia...
AGN: 240.22 (+2.88), ACAD: 34.45 (-0.54)
Gastric Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gc9gpc/gastric_cancer) has announced the addition of the "Gastric Cancer Partnering 2010-2015" report to their offering. The Gastric Cancer Partnering 2010-2015 provides understanding and access to the gastric cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of gastric cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gastric cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 40 links to online copies of actual gastric cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in gastric cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 40 gastric cancer deals and contract documents where available - The leading gastric cancer deals by value since 2010 In Gastric Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Gastric cancer partnering Chapter 3 - Average deal terms for Gastric cancer Chapter 4 - Active Gastric cancer dealmakers Chapter 5 - Gastric cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/gc...ric_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Head and Neck Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xhfvh/head_and_neck) has announced the addition of the "Head and Neck Cancer Partnering 2010-2015" report to their offering. The Head and Neck Cancer Partnering 2010-2015 provides understanding and access to the head and neck cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of head and neck cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors head and neck cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 40 links to online copies of actual head and neck cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in head and neck cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 40 head and neck cancer deals and contract documents where available - The leading head and neck cancer deals by value since 2010 In Head and Neck Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Head and neck cancer partnering Chapter 3 - Average deal terms for Head and neck cancer Chapter 4 - Active Head and neck cancer dealmakers Chapter 5 - Head and neck cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/9x...d_and_neck
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Leukemia Partnering Deals and Agreements Analysis Report 2015
M2 - Thu Mar 19, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j4wxkq/leukemia) has announced the addition of the "Leukemia Partnering 2010-2015" report to their offering. The Leukemia Partnering 2010-2015 provides understanding and access to the leukemia partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of leukemia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors leukemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 150 links to online copies of actual leukemia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in leukemia dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 90 leukemia deals and contract documents where available - The leading leukemia deals by value since 2010 In Leukemia Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Leukemia partnering Chapter 3 - Average deal terms for Leukemia Chapter 4 - Active Leukemia dealmakers Chapter 5 - Leukemia dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/j4wxkq/leukemia
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Bladder Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v27kf6/bladder_cancer) has announced the addition of the "Bladder Cancer Partnering 2010-2015" report to their offering. The Bladder Cancer Partnering 2010-2015 provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of bladder cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bladder cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 35 links to online copies of actual bladder cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in bladder cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 bladder cancer deals - The leading bladder cancer deals by value since 2010 In Bladder Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in bladder cancer partnering Chapter 3 - Average deal terms for bladder cancer Chapter 4 - Active bladder cancer dealmakers Chapter 5 - Bladder cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - 30 of the 48 Companies Featured - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini For more information visit http://www.researchandmarkets.com/research/v2...der_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), CELGZ: 3.05 (+0.02)
Brain Cancer Partnering Deals and Agreements 2010-2015
M2 - Thu Mar 19, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t72fs6/brain_cancer) has announced the addition of the "Brain Cancer Partnering 2010-2015" report to their offering. The Brain Cancer Partnering 2010-2015 provides understanding and access to the brain cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of brain cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors brain cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 90 links to online copies of actual brain cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in brain cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - The leading brain cancer deals by value since 2010 In Brain Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in brain cancer partnering Chapter 3 - Average deal terms for brain cancer Chapter 4 - Active brain cancer dealmakers Chapter 5 - Brain cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - 30 of the 48 Companies - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini For more information visit http://www.researchandmarkets.com/research/t7...ain_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), CELGZ: 3.05 (+0.02)
Discovery Stage Partnering Terms and Agreements Deals 2015
M2 - Thu Mar 19, 6:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqchj2/discovery_stage) has announced the addition of the "Discovery Stage Partnering Terms and Agreements" report to their offering. The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Why do companies partner at discovery stage? Chapter 3 - Discovery stage deal strategies and structure Chapter 4 - Discovery stage partnering payment strategies Chapter 5 - Trends in discovery stage deal making Chapter 6 - Average payment terms for discovery stage partnering Chapter 7 - Leading discovery stage deals Chapter 8 - Big pharma and big biotech discovery stage partnering deals Chapter 9 - Discovery stage partnering contracts directory Chapter 10 - Discovery stage dealmaking directory by year Companies Mentioned - 30 of the 98 Companies Featured - Abbott - Abbvie - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Bayer Animal Health - Bayer CropScience - Bayer Healthcare - Bayer Innovation - Bayer Schering Pharma - Bayer Technology Services - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical - CSL - CSL Biotherapies - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Eli Lilly - Endo Pharmaceuticals - Fresenius - Fresenius Kabi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/jq...very_stage
AGN: 240.22 (+2.88), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), BAX: 68.18 (+0.20), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56), CELGZ: 3.05 (+0.02)
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharmaceuticals, Endo International and Allergan - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 8:30AM CDT
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharmaceuticals, Endo International and Allergan
AGN: 240.22 (+2.88), ENDP: 92.37 (+0.89), VRX: 204.26 (+2.17), SLXP: 172.80 (+0.26)
Actavis' pending acquisition of Allergan approved by European Commission
M2 - Wed Mar 18, 6:41AM CDT
Pharmaceutical company Actavis (NYSE:ACT) reported on Tuesday that it has received clearance from the European Commission for its pending acquisition of Allergan (NYSE:AGN).
AGN: 240.22 (+2.88), ACT: 317.06 (+2.65)
Trend Is Not Your Friend - Cramer's Mad Money (3/17/15)
SA Editor Mohit Manghnani - Seeking Alpha - Wed Mar 18, 6:30AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday, March 17. Cramer said that 2015 is a new ballgame altogether and the trend is not a friend. "Why can't we put together a winning streak? Why can't we go up...
TSLA: 198.08 (+2.43), MU: 28.68 (+0.63), ACT: 317.06 (+2.65), GE: 25.40 (+0.07), CYBR: 48.69 (-1.72), STX: 56.51 (+0.80), PFE: 34.25 (+0.10), M: 65.98 (+0.91), LL: 28.51 (-0.84), INTC: 31.31 (+0.57), HPQ: 33.28 (+0.44), SBUX: 97.46 (-0.30), JACK: 97.07 (+0.42), AGN: 240.22 (+2.88), URBN: 47.01 (+0.31), CMG: 686.65 (+5.98), MRK: 58.58 (+0.37), GM: 38.87 (+0.22), MSFT: 42.88 (+0.60), AAPL: 125.90 (-1.60)
Why Pfizer Inc. Isn't Built to Last
George Budwell, The Motley Fool - Motley Fool - Sat Mar 21, 7:11AM CDT
Source: Wikimedia. Nearly all big pharma these days have been undergoing wholesale changes due to the patent cliff, the emergence of game-changing new classes of drugs, and payers leveraging their formularies to induce pricing wars. A direct...
AGN: 240.22 (+2.88), MRK: 58.58 (+0.37), AZN: 72.70 (+1.80), PFE: 34.25 (+0.10), GSK: 48.81 (+0.60)
Douglas Ingram of Allergan, Inc. Elected to the Board of Pacific Mutual Holding Company
Business Wire - Thu Mar 19, 3:05PM CDT
Pacific Life announced today that Douglas Ingram, former president of Allergan, Inc., has been elected to the board of Pacific Mutual Holding Company, the ultimate parent company of Pacific Life Insurance Company. His election is effective May 1, 2015.
AGN: 240.22 (+2.88)
Shares of AGN Up 43.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 19, 11:20AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 6 months, Allergan has returned 43.75% as of today's recent price of $240.22.
AGN: 240.22 (+2.88)
2010-2015 Myocardial Infarction Partnering Deals and Agreements Deals Analysis for the World's Leading Healthcare Companies
M2 - Thu Mar 19, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4q8bs6/myocardial) has announced the addition of the "Myocardial Infarction Partnering 2010-2015" report to their offering. The Myocardial Infarction Partnering 2010-2015 provides understanding and access to the myocardial infarction partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of myocardial infarction partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors myocardial infarction technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. In Myocardial infarction Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in myocardial infarction partnering Chapter 3 - Average deal terms for myocardial infarction Chapter 4 - Active myocardial infarction dealmakers Chapter 5 - Myocardial infarction dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/4q8bs6/myocardial
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Prostate Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 10:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6kbqqw/prostate_cancer) has announced the addition of the "Prostate Cancer Partnering 2010-2015" report to their offering. The Prostate cancer Partnering 2010-2015 provides understanding and access to the prostate cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of prostate cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors prostate cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in prostate cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 100 prostate cancer deals and contract documents where available - The leading prostate cancer deals by value since 2010 In Prostate cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Prostate cancer partnering Chapter 3 - Average deal terms for Prostate cancer Chapter 4 - Active Prostate cancer dealmakers Chapter 5 - Prostate cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/6k...ate_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Solid Tumor Partnering Deals and Agreements Anaysis for the World's Leading Healthcare Companies 2010-2015
M2 - Thu Mar 19, 10:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmmk8v/solid_tumor) has announced the addition of the "Solid Tumor Partnering 2010-2015" report to their offering. The Solid Tumor Cancer Partnering 2010-2015 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of solid tumor cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors solid tumor cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 200 links to online copies of actual solid tumor cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In Solid Tumor Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Solid tumor cancer partnering Chapter 3 - Average deal terms for Solid tumor cancer Chapter 4 - Active Solid tumor cancer dealmakers Chapter 5 - Solid tumor cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/bm...olid_tumor
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Lung Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rq7vtm/lung_cancer) has announced the addition of the "Lung Cancer Partnering 2010-2015" report to their offering. The Lung Cancer Partnering 2010-2015 provides understanding and access to the lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of lung cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lung cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in lung cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 190 lung cancer deala and contract documents where available - The leading lung cancer deals by value since 2010 In Lung Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Lung cancer partnering Chapter 3 - Average deal terms for Lung cancer Chapter 4 - Active Lung cancer dealmakers Chapter 5 - Lung cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/rq...ung_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Lymphoma Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5hkfxz/lymphoma) has announced the addition of the "Lymphoma Partnering 2010-2015" report to their offering. The Lymphoma Partnering 2010-2015 provides understanding and access to the lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of lymphoma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lymphoma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 100 links to online copies of actual lymphoma deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in lymphoma dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 100 lymphoma deals and contract documents where available - The leading lymphoma deals by value since 2010 In Lymphoma Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Lymphoma partnering Chapter 3 - Average deal terms for Lymphoma Chapter 4 - Active Lymphoma dealmakers Chapter 5 - Lymphoma dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/5hkfxz/lymphoma
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Multiple Myeloma Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bttdtp/multiple_myeloma) has announced the addition of the "Multiple Myeloma Partnering 2010-2015" report to their offering. The Multiple myeloma Partnering 2010-2015 provides understanding and access to the multiple myeloma partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of multiple myeloma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors multiple myeloma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in multiple myeloma dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 100 multiple myeloma contract documents - The leading multiple myeloma deals by value since 2010 In Multiple myeloma Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in multiple myeloma partnering Chapter 3 - Leading multiple myeloma deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Companies Mentioned - Abbott - Allergan - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/bt...le_myeloma
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Liver Cancer Partnering Deals and Agreements 2010-2015 - Analysis from the World's Leading Healthcare Companies
M2 - Thu Mar 19, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8sxzpx/liver_cancer) has announced the addition of the "Liver Cancer Partnering 2010-2015" report to their offering. The Liver Cancer Partnering 2010-2015 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in Liver cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 livercancer deals and contract documents where available - The leading Liver cancer deals by value since 2010 In Liver Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Liver cancer partnering Chapter 3 - Average deal terms for Liver cancer Chapter 4 - Active Liver cancer dealmakers Chapter 5 - Liver cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/8s...ver_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
This Exciting Biotech Isn't Built to Last
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Mar 19, 7:04AM CDT
Source: Flickr, Courtesy of Creative Commons The performance of an exciting biotech can really pack some punch in your portfolio, but some of them simply aren't built to last. One candidate for that category is San Diego-based Acadia...
AGN: 240.22 (+2.88), ACAD: 34.45 (-0.54)
Gastric Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gc9gpc/gastric_cancer) has announced the addition of the "Gastric Cancer Partnering 2010-2015" report to their offering. The Gastric Cancer Partnering 2010-2015 provides understanding and access to the gastric cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of gastric cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gastric cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 40 links to online copies of actual gastric cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in gastric cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 40 gastric cancer deals and contract documents where available - The leading gastric cancer deals by value since 2010 In Gastric Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Gastric cancer partnering Chapter 3 - Average deal terms for Gastric cancer Chapter 4 - Active Gastric cancer dealmakers Chapter 5 - Gastric cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/gc...ric_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Head and Neck Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xhfvh/head_and_neck) has announced the addition of the "Head and Neck Cancer Partnering 2010-2015" report to their offering. The Head and Neck Cancer Partnering 2010-2015 provides understanding and access to the head and neck cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of head and neck cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors head and neck cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 40 links to online copies of actual head and neck cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in head and neck cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 40 head and neck cancer deals and contract documents where available - The leading head and neck cancer deals by value since 2010 In Head and Neck Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Head and neck cancer partnering Chapter 3 - Average deal terms for Head and neck cancer Chapter 4 - Active Head and neck cancer dealmakers Chapter 5 - Head and neck cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/9x...d_and_neck
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Leukemia Partnering Deals and Agreements Analysis Report 2015
M2 - Thu Mar 19, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j4wxkq/leukemia) has announced the addition of the "Leukemia Partnering 2010-2015" report to their offering. The Leukemia Partnering 2010-2015 provides understanding and access to the leukemia partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of leukemia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors leukemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 150 links to online copies of actual leukemia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in leukemia dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 90 leukemia deals and contract documents where available - The leading leukemia deals by value since 2010 In Leukemia Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Leukemia partnering Chapter 3 - Average deal terms for Leukemia Chapter 4 - Active Leukemia dealmakers Chapter 5 - Leukemia dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/j4wxkq/leukemia
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), MRK: 58.58 (+0.37), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), NVS: 101.68 (+1.81)
Bladder Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v27kf6/bladder_cancer) has announced the addition of the "Bladder Cancer Partnering 2010-2015" report to their offering. The Bladder Cancer Partnering 2010-2015 provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of bladder cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bladder cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 35 links to online copies of actual bladder cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in bladder cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 bladder cancer deals - The leading bladder cancer deals by value since 2010 In Bladder Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in bladder cancer partnering Chapter 3 - Average deal terms for bladder cancer Chapter 4 - Active bladder cancer dealmakers Chapter 5 - Bladder cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - 30 of the 48 Companies Featured - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini For more information visit http://www.researchandmarkets.com/research/v2...der_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), CELGZ: 3.05 (+0.02)
Brain Cancer Partnering Deals and Agreements 2010-2015
M2 - Thu Mar 19, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t72fs6/brain_cancer) has announced the addition of the "Brain Cancer Partnering 2010-2015" report to their offering. The Brain Cancer Partnering 2010-2015 provides understanding and access to the brain cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of brain cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors brain cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 90 links to online copies of actual brain cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in brain cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - The leading brain cancer deals by value since 2010 In Brain Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in brain cancer partnering Chapter 3 - Average deal terms for brain cancer Chapter 4 - Active brain cancer dealmakers Chapter 5 - Brain cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - 30 of the 48 Companies - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini For more information visit http://www.researchandmarkets.com/research/t7...ain_cancer
AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), GILD: 102.29 (+0.85), BAX: 68.18 (+0.20), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), FRX: 99.00 (-0.77), CELGZ: 3.05 (+0.02)
Discovery Stage Partnering Terms and Agreements Deals 2015
M2 - Thu Mar 19, 6:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqchj2/discovery_stage) has announced the addition of the "Discovery Stage Partnering Terms and Agreements" report to their offering. The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Why do companies partner at discovery stage? Chapter 3 - Discovery stage deal strategies and structure Chapter 4 - Discovery stage partnering payment strategies Chapter 5 - Trends in discovery stage deal making Chapter 6 - Average payment terms for discovery stage partnering Chapter 7 - Leading discovery stage deals Chapter 8 - Big pharma and big biotech discovery stage partnering deals Chapter 9 - Discovery stage partnering contracts directory Chapter 10 - Discovery stage dealmaking directory by year Companies Mentioned - 30 of the 98 Companies Featured - Abbott - Abbvie - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Bayer Animal Health - Bayer CropScience - Bayer Healthcare - Bayer Innovation - Bayer Schering Pharma - Bayer Technology Services - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical - CSL - CSL Biotherapies - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Eli Lilly - Endo Pharmaceuticals - Fresenius - Fresenius Kabi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/jq...very_stage
AGN: 240.22 (+2.88), ENDP: 92.37 (+0.89), BIIB: 475.98 (+42.33), BAX: 68.18 (+0.20), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56), CELGZ: 3.05 (+0.02)
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharmaceuticals, Endo International and Allergan - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 8:30AM CDT
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharmaceuticals, Endo International and Allergan
AGN: 240.22 (+2.88), ENDP: 92.37 (+0.89), VRX: 204.26 (+2.17), SLXP: 172.80 (+0.26)
Actavis' pending acquisition of Allergan approved by European Commission
M2 - Wed Mar 18, 6:41AM CDT
Pharmaceutical company Actavis (NYSE:ACT) reported on Tuesday that it has received clearance from the European Commission for its pending acquisition of Allergan (NYSE:AGN).
AGN: 240.22 (+2.88), ACT: 317.06 (+2.65)
Trend Is Not Your Friend - Cramer's Mad Money (3/17/15)
SA Editor Mohit Manghnani - Seeking Alpha - Wed Mar 18, 6:30AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday, March 17. Cramer said that 2015 is a new ballgame altogether and the trend is not a friend. "Why can't we put together a winning streak? Why can't we go up...
TSLA: 198.08 (+2.43), MU: 28.68 (+0.63), ACT: 317.06 (+2.65), GE: 25.40 (+0.07), CYBR: 48.69 (-1.72), STX: 56.51 (+0.80), PFE: 34.25 (+0.10), M: 65.98 (+0.91), LL: 28.51 (-0.84), INTC: 31.31 (+0.57), HPQ: 33.28 (+0.44), SBUX: 97.46 (-0.30), JACK: 97.07 (+0.42), AGN: 240.22 (+2.88), URBN: 47.01 (+0.31), CMG: 686.65 (+5.98), MRK: 58.58 (+0.37), GM: 38.87 (+0.22), MSFT: 42.88 (+0.60), AAPL: 125.90 (-1.60)
